These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

353 related items for PubMed ID: 16573804

  • 1. Comparison of the efficacy and safety of Eudragit-L-coated mesalazine tablets with ethylcellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis.
    Gibson PR, Fixa B, Pekárková B, Bátovský M, Radford-Smith G, Tibitanzl J, Gabalec L, Florin TH, Greinwald R.
    Aliment Pharmacol Ther; 2006 Apr 01; 23(7):1017-26. PubMed ID: 16573804
    [Abstract] [Full Text] [Related]

  • 2. Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis--results from a randomized-controlled trial.
    Raedler A, Behrens C, Bias P.
    Aliment Pharmacol Ther; 2004 Dec 01; 20(11-12):1353-63. PubMed ID: 15606398
    [Abstract] [Full Text] [Related]

  • 3. A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis.
    Marakhouski Y, Fixa B, Holomán J, Hulek P, Lukas M, Bátovský M, Rumyantsev VG, Grigoryeva G, Stolte M, Vieth M, Greinwald R, International Salofalk Study Group.
    Aliment Pharmacol Ther; 2005 Jan 15; 21(2):133-40. PubMed ID: 15679762
    [Abstract] [Full Text] [Related]

  • 4. Mesalazine granules are superior to Eudragit-L-coated mesalazine tablets for induction of remission in distal ulcerative colitis - a pooled analysis.
    Leifeld L, Pfützer R, Morgenstern J, Gibson PR, Marakhouski Y, Greinwald R, Mueller R, Kruis W.
    Aliment Pharmacol Ther; 2011 Nov 15; 34(9):1115-22. PubMed ID: 21923715
    [Abstract] [Full Text] [Related]

  • 5. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
    Hanauer SB, Sandborn WJ, Kornbluth A, Katz S, Safdi M, Woogen S, Regalli G, Yeh C, Smith-Hall N, Ajayi F.
    Am J Gastroenterol; 2005 Nov 15; 100(11):2478-85. PubMed ID: 16279903
    [Abstract] [Full Text] [Related]

  • 6. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study.
    D'Haens G, Hommes D, Engels L, Baert F, van der Waaij L, Connor P, Ramage J, Dewit O, Palmen M, Stephenson D, Joseph R.
    Aliment Pharmacol Ther; 2006 Oct 01; 24(7):1087-97. PubMed ID: 16984503
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis.
    Sandborn WJ, Regula J, Feagan BG, Belousova E, Jojic N, Lukas M, Yacyshyn B, Krzeski P, Yeh CH, Messer CA, Hanauer SB.
    Gastroenterology; 2009 Dec 01; 137(6):1934-43.e1-3. PubMed ID: 19766640
    [Abstract] [Full Text] [Related]

  • 11. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study.
    Scherl EJ, Pruitt R, Gordon GL, Lamet M, Shaw A, Huang S, Mareya S, Forbes WP.
    Am J Gastroenterol; 2009 Jun 01; 104(6):1452-9. PubMed ID: 19491859
    [Abstract] [Full Text] [Related]

  • 12. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis.
    Lichtenstein GR, Kamm MA, Boddu P, Gubergrits N, Lyne A, Butler T, Lees K, Joseph RE, Sandborn WJ.
    Clin Gastroenterol Hepatol; 2007 Jan 01; 5(1):95-102. PubMed ID: 17234558
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.
    Dignass AU, Bokemeyer B, Adamek H, Mross M, Vinter-Jensen L, Börner N, Silvennoinen J, Tan G, Pool MO, Stijnen T, Dietel P, Klugmann T, Vermeire S, Bhatt A, Veerman H.
    Clin Gastroenterol Hepatol; 2009 Jul 01; 7(7):762-9. PubMed ID: 19375519
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis.
    Eliakim R, Tulassay Z, Kupcinskas L, Adamonis K, Pokrotnieks J, Bar-Meir S, Lavy A, Mueller R, Greinwald R, Chermesh I, Gross V, International Salofalk Foam Study Group.
    Aliment Pharmacol Ther; 2007 Nov 01; 26(9):1237-49. PubMed ID: 17944738
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.